Subcellular Localization and Transport Kinetics of Ruthenium Organometallic Anticancer Compounds in Living Cells: A Dose-Dependent Role for Amino Acid and Iron Transporters
Citations Over TimeTop 10% of 2014 papers
Abstract
Ruthenium-based compounds are developed for anticancer treatment, but their mode of action including their import mechanism and subcellular localization remains elusive. Here, we used the intrinsic luminescent properties of cytotoxic organoruthenium (Ru(II)) compounds obtained with an anionic cyclometalated 2-phenylpyridine chelate and neutral aromatic chelating ligands (e.g., phenanthrolines) to follow their behavior in living cells. We established that the difference in sensitivity between cancer cells and noncancerous cells toward one of the compounds correlates with its import kinetics and follows a balance between active and passive transport. The active-transport mechanism involves iron and amino-acid transporters, which are transcriptionally regulated by the drug. We also demonstrated a correlation between the accumulation of these compounds in specific compartments (endoplasmic reticulum, nucleus, mitochondria) and the activation of specific cytotoxic mechanisms such as the mitochondrial stress pathway. Our study pinpoints a novel and complex mechanism of accumulation of ruthenium drugs in cancer cells.
Related Papers
- → Ligand control of metal oxidation states. Synthesis, characterization and cyclic voltammetric studies of a group of ruthenium phenolates(1996)18 cited
- THE FEATURES OF PROTEIN BINDING BY RUTHENIUM COMPLEXES: DOCKING, FORCE FIELD AND QM/MM STUDIES(2013)
- → ChemInform Abstract: Synthesis, Reactivities, and Structural Studies on High‐Valent Ruthenium Oxo Complexes. Ruthenium(IV), Ruthenium(V), and Ruthenium(VI) Oxo Complexes of Tertiary Amine Ligands.(1987)
- → Well-Defined Surface-Bonded Ruthenium Complexes with Molecular Nitrogen(1998)
- → ANALYSIS BY THE RFES METHOD OF CATALYTIC SYSTEMS BASED ON RUTHENIUM(2023)